Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-16

Clinical Trial Update: Janagliflozin Treat T2DM Monotherapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for janagliflozin as monotherapy in type 2 diabetes is in development, with the status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • janagliflozin (janagliflozin)

Snippet

Sponsor: Sihuan Pharmaceutical Holdings Group Ltd. | Conditions: Diabetes Type 2 | Phase 3 | Status: UNKNOWN